ArticleFrontiers in oncology2025
Immune mediation between sarcopenia, performance status, and survival in gastric cancer patients undergoing radical resection.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to explore the combined impact of sarcopenia and physical performance on immune status and prognosis in patients with resectable gastric cancer, and to evaluate the mediating role of immune function. Methods: A retrospective cohort of 413 patients undergoing radical gastrectomy was analyzed. Sarcopenia was assessed by skeletal muscle index (SMI) on CT, and physical performance by ECOG score. Patients were stratified into ISPS (Integrated Sarcopenia and Performance Status) high, medium, and low groups. Peripheral lymphocyte subsets were measured preoperatively. Kaplan-Meier curves, Cox regression, and mediation analysis were used to examine survival and immune interactions. Prognostic nomograms were constructed based on independent variables. Results: Lower ISPS scores were significantly associated with reduced CD3 Conclusion: Sarcopenia and poor functional status are linked to impaired immunity and unfavorable outcomes in gastric cancer. Immune status may partially explain this relationship. ISPS may serve as a useful prognostic tool, and integrating physical and immune assessments could improve prognostic evaluation and support personalized perioperative strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.